On 18 August WHOOP made Advanced Labs available without a wearable membership for the first time, and added Galleri, GRAIL’s multi-cancer early detection test. One blood draw at any of nearly 2,000 Quest locations. WHOOP prices Galleri at $799, a one-time cost it recommends annually. Eleven days earlier, GRAIL had confirmed that an FDA advisory committee will meet on 23 September to review the test.
Advanced Labs is not new. It launched in September 2025, behind a WHOOP membership. The panels are the same. What changed is the gate.
A company whose business was a wrist strap and a monthly subscription is now selling diagnostics to people who own neither. That is a different company from the one that existed in July, and the cancer test is the clearest sign of it.
Why a cancer test can be sold without FDA approval
Start with the fact most readers will assume is a scandal and is not.
Galleri has not been cleared or approved by the Food and Drug Administration. GRAIL states this plainly in its own patient materials. It is a laboratory developed test, performed inside GRAIL’s CLIA-certified and CAP-accredited laboratory, and available by prescription only.
Under that framework, FDA approval is not currently required to market it, and that has been true for years.
Laboratory developed tests occupy a category that has been contested for a decade. The FDA finalised a rule in 2024 that would have brought them under medical device regulation. In March 2025 a federal court in the Eastern District of Texas held that the agency lacked the authority, and vacated the rule. By September 2025 the FDA had formally rescinded it and returned to enforcement discretion.
So the reason a cancer screening test can be bought through a fitness brand without FDA approval is not a loophole anybody found. It is the settled state of American law, arrived at eighteen months ago in a courtroom, and it applies to a great deal more than this one test.
It is not a loophole anybody found. It is the settled state of American law.
What the test finds, and what it does not
Galleri looks for cancer-specific methylation patterns in blood, and is designed to detect signals associated with more than 50 types of cancer before symptoms appear.
GRAIL’s own limitations are worth reading slowly, because they are the part that gets lost between a press release and a checkout page.
The test does not detect a signal for all cancers. A Cancer Signal Detected result is not a cancer diagnosis and requires follow-up diagnostic testing. False positives and false negatives occur. A result of No Cancer Signal Detected does not completely rule out the possibility of cancer. And it is intended to be used in addition to, not as a replacement for, guideline-recommended screening.
WHOOP says tests through Advanced Labs are reviewed and ordered by a licensed healthcare provider, and that every report is reviewed by a licensed clinician.
None of that is unusual for a screening test. Every screening test in medicine carries some version of it. What is unusual is where the conversation now begins: not in a physician’s office raising it with a patient, but on a product page next to a sleep score.
The part nobody is saying out loud
On 7 August, GRAIL confirmed that the FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will meet on 23 September 2026 to review its premarket approval application for Galleri. The submission carries performance and safety results from 25,490 consented participants in the PATHFINDER 2 study with one year of follow-up, alongside data from the NHS-Galleri trial.
Read that against the paragraph above and the interesting thing inverts.
GRAIL is not being dragged in front of a regulator. Under current law it does not need premarket approval to sell Galleri at all. It applied anyway, with a 25,490-participant dataset, and the advisory committee meets because the company asked for the meeting.
The obvious story is that a test slipped into a consumer channel five weeks before the FDA looked at it. The truer story is that the only reason the FDA will ever render a verdict on this test is that its maker volunteered for one, in a market where nobody made it.
Which means 23 September is worth watching for a reason that has nothing to do with WHOOP. It is the first time a federal regulator will say, on the record, whether a multi-cancer blood test does what its makers say it does. Whatever the panel concludes will travel far past one company and one wrist strap.